Compare DHC & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHC | HUMA |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.4M | 236.0M |
| IPO Year | N/A | N/A |
| Metric | DHC | HUMA |
|---|---|---|
| Price | $4.71 | $1.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $5.25 | ★ $10.13 |
| AVG Volume (30 Days) | 815.9K | ★ 4.3M |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,537,901,000.00 | $1,571,000.00 |
| Revenue This Year | $4.79 | N/A |
| Revenue Next Year | $3.32 | $731.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.10 | N/A |
| 52 Week Low | $2.00 | $1.09 |
| 52 Week High | $4.99 | $6.77 |
| Indicator | DHC | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 47.73 |
| Support Level | $4.65 | $1.21 |
| Resistance Level | $4.99 | $1.32 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 44.33 | 55.88 |
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. It operates through two segments: Office Portfolio and SHOP. The office portfolio includes medical office properties leased to medical-related businesses and life sciences properties. The SHOP segment runs communities that offer multiple types of residential care, ranging from independent living to nursing services. DHT operates across the United States and the majority of its revenue derives from rents and medical programs. Majority of revenue is from SHOP segment.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.